Corbus Pharmaceuticals Holdings, Inc.
CRBP
$6.68
$0.5458.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 78.01% | -18.70% | |||
| Gross Profit | -78.01% | 18.70% | |||
| SG&A Expenses | 8.25% | -18.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 56.88% | -18.70% | |||
| Operating Income | -56.88% | 18.70% | |||
| Income Before Tax | -78.15% | 30.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -78.15% | 30.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -78.15% | 30.86% | |||
| EBIT | -56.88% | 18.70% | |||
| EBITDA | -57.92% | 18.77% | |||
| EPS Basic | -77.81% | 31.79% | |||
| Normalized Basic EPS | -77.83% | 31.80% | |||
| EPS Diluted | -77.81% | 31.79% | |||
| Normalized Diluted EPS | -77.83% | 31.80% | |||
| Average Basic Shares Outstanding | 0.19% | 1.37% | |||
| Average Diluted Shares Outstanding | 0.19% | 1.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||